ICML 2017 | The potential of biosimilar rituximab: reducing budgets and increasing access to treatment
Laszlo Gulacsi, MD, PhD from Corvinus University Budapest, Budapest, Hungary gives an overview of his talk on ‘Reducing budget, increasing access’ held at the International Conference on Malignant Lymphoma (ICML) 2017 in Lugano, Switzerland. Prof. Gulacsi explains that their study analyzed the budgetary impact of the introduction of the biosimilar rituximab for all indications in 28 European Union countries using a budget impact analysis model. The potential budget savings were found to be 90 million Euros in the first year and up to 600 million Euros over three years. This would allow for the treatment of an additional 50,000 patients if the budget saving were used to allow more patients access to treatment. Prof. Gulasci further explains Health Technology Assessment (HTA) requirements as well as who the key decision makers are.
This video has been supported by Napp Pharmaceuticals Ltd through an unrestricted educational grant to Magdalen Medical Publishing.
